Clinical Trial Links Daily Tomato Consumption to Reduced Liver Fat in MASLD Patients
A recent study published in the journal Nutrients has highlighted the potential benefits of daily tomato consumption for individuals with metabolic dysfunction-associated steatotic liver disease (MASLD). The randomized POMOSANO trial involved 79 adults diagnosed with MASLD, who were assigned to either consume 200 grams of raw tomatoes—approximately two medium-sized tomatoes—and 50 grams of tomato sauce daily, or to avoid tomatoes for six weeks. The findings showed that participants in the tomato group experienced a median reduction in liver fat of 35 units, while those in the control group, who refrained from eating tomatoes, had a median reduction of only 18 units. This significant difference suggests that tomatoes may play a role in supporting metabolic health.
MASLD, previously known as non-alcoholic fatty liver disease (NAFLD), is characterized by the accumulation of excess fat in the liver and is often associated with conditions such as obesity, Type 2 diabetes, and high cholesterol levels. According to health authorities, an estimated 1.3 billion people worldwide were living with MASLD in 2023, reflecting a dramatic increase of 143% since 1990. Projections indicate that this number could rise to 1.8 billion by 2050.
The researchers utilized FibroScan technology, a noninvasive method, to measure liver fat scores before and after the six-week intervention. Participants were instructed to maintain their usual dietary and lifestyle habits throughout the trial. The choice of tomatoes for this study was based on their status as a staple in the Mediterranean diet and their rich content of lycopene, a plant compound known for its antioxidant and anti-inflammatory properties.
Interestingly, the larger reduction in liver fat observed in the tomato group was not attributed to weight loss, as there were no significant differences in body weight, body mass index, or body fat between the two groups. This finding suggests that the tomatoes themselves may have contributed to the reduction in liver fat.
While no significant changes were noted in liver stiffness, blood sugar, cholesterol levels, liver enzymes, or inflammation markers after six weeks, the researchers acknowledged that the duration of the study might have been too short for these measures to show meaningful changes. They emphasized the need for larger and longer studies to determine the sustainability of the observed effects and whether they translate into broader metabolic improvements.
Tomatoes are rich in various beneficial compounds, including lycopene, beta-carotene, and polyphenols, which may help protect cells from oxidative stress and promote a healthier inflammatory response. Previous research has indicated that lycopene can alleviate symptoms associated with NAFLD. Additionally, cooking tomatoes can enhance the bioavailability of lycopene, making it easier for the body to absorb. The study suggests that pairing tomatoes with a source of fat, such as olive oil, can further improve nutrient absorption.
Incorporating tomatoes into the diet can be simple; they can be added to salads, sandwiches, pasta dishes, or enjoyed as a quick snack. However, the study authors caution that while tomatoes can be a valuable part of a balanced diet, they should not be viewed as a standalone treatment for MASLD. Instead, they should be included as part of a nutrient-rich eating pattern. Broader dietary patterns that emphasize whole foods and vegetables have been linked to a lower risk of chronic liver disease.
In conclusion, the six-week trial indicates that daily tomato consumption may lead to a greater reduction in liver fat among individuals with MASLD. The researchers call for further investigation to understand the long-term effects of this dietary intervention and its potential role in managing liver health.




